Regression of Symptoms After Selective Iron Chelation Therapy in a Case of Neurodegeneration with Brain Iron AccumulationLUCA FOMI, Gian; BALOCCO, Manuela; CREMONESI, Laura et al.Movement disorders. 2008, Vol 23, Num 6, pp 905-908, issn 0885-3185, 4 p.Article

Fatal congestive heart failure with deferiproneAQODAD, N; LOREAL, O; ERDTMAN, L et al.Gastroentérologie clinique et biologique. 2008, Vol 32, Num 6-7, pp 656-657, issn 0399-8320, 2 p.Article

Chelating Agents for the Treatment of Systemic Iron OverloadMA, Y; ZHOU, T; KONG, X et al.Current medicinal chemistry. 2012, Vol 19, Num 17, pp 2816-2827, issn 0929-8673, 12 p.Article

Traitement des surcharges en fer : place du déférasirox, nouveau chélateur oral du fer = Treatment of iron overload : usefulness of deferasirox, a new oral chelator of ironLAINE, F; DEUGNIER, Y.La Lettre du pharmacologue (Boulogne). 2007, Vol 21, Num 3, pp 68-72, issn 0984-452X, 5 p.Article

Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004TELFER, Paul; COEN, Pietro G; SITAROU, Maria et al.Haematologica (Roma). 2006, Vol 91, Num 9, pp 1187-1192, issn 0390-6078, 6 p.Article

The combined effects of the chelating agent deferiprone, ascorbic acid and mesna on urinary aluminum excretion in rabbitsPING, L; XI, C; SHIDE, W et al.Trace elements and electrolytes. 2003, Vol 20, Num 2, pp 79-82, issn 0946-2104, 4 p.Article

Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patientsMOURAD, Fadi H; HOFFBRAND, A. Victor; SHEIKH-TAHA, Marwan et al.British journal of haematology. 2003, Vol 121, Num 1, pp 187-189, issn 0007-1048, 3 p.Article

Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromesMERKEL, Drorit G; NAGLER, Arnon.Expert review of anticancer therapy. 2014, Vol 14, Num 7, pp 817-829, issn 1473-7140, 13 p.Article

Lipophilicity of kinetically labile metal complexes through the example of antidiabetic Zn(II) and VO(IV) compoundsENYEDY, Eva A; HOLLENDER, Dominik; KISS, Tamás et al.Journal of pharmaceutical and biomedical analysis. 2011, Vol 54, Num 5, pp 1073-1081, issn 0731-7085, 9 p.Article

A pilot trial of deferiprone for neurodegeneration with brain iron accumulationABBRUZZESE, Giovanni; COSSU, Giovanni; BONUCCELLI, Ubaldo et al.Haematologica (Roma). 2011, Vol 96, Num 11, pp 1708-1711, issn 0390-6078, 4 p.Article

Iron chelation therapy in the management of thalassemia: the Asian perspectivesVIPRAKASIT, Vip; LEE-LEE, Chan; QUAH THUAN CHONG et al.International journal of hematology. 2009, Vol 90, Num 4, pp 435-445, issn 0925-5710, 11 p.Article

La chélation du fer en 1998 = Iron chelationDE MONTALEMBERT, M.Transfusion clinique et biologique (Paris). 1998, Vol 5, Num 5, pp 353-356, issn 1246-7820Article

UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteersMICHAEL GEORGE LIMENTA, Lie; JIRASOMPRASERT, Totsapol; TANKANITLERT, Jeeranut et al.British journal of clinical pharmacology. 2008, Vol 65, Num 6, pp 908-916, issn 0306-5251, 9 p.Article

Les progrès dans le traitement chélateur du fer = Progress in iron chelation therapyRONSON, Aaron; HERSHKO, Chaim.Hématologie (Montrouge). 2008, Vol 14, Num 5, pp 378-385, issn 1264-7527, 8 p.Article

Combined therapy with deferiprone and desferrioxamine in thalassemia majorORIGA, Raffaella; BINA, Patrizio; AGUS, Annalisa et al.Haematologica (Roma). 2005, Vol 90, Num 10, pp 1309-1314, issn 0390-6078, 6 p.Article

The Fenton Activity of Iron(III) in the Presence of DeferiproneDEVANUR, Lakshmi D; NEUBERT, Hendrik; HIDER, Robert C et al.Journal of pharmaceutical sciences. 2008, Vol 97, Num 4, pp 1454-1467, issn 0022-3549, 14 p.Article

Influence of the chelator 1,2-dimethyl-3-hydroxypyrid-4-one on aluminum elimination in aluminum-loaded rabbitsXI, C; PING, L; WUSHIDE et al.Trace elements and electrolytes. 1997, Vol 14, Num 3, pp 130-133, issn 0946-2104Article

Oral Iron chelation therapy with Deferiprone in patients with Thalassemia MajorSAJID, Raihan; GHANI, Farooq; ADIL, Salman et al.Journal of the Pakistan Medical Association. 2009, Vol 59, Num 6, pp 388-390, issn 0030-9982, 3 p.Article

Surcharge en fer d'origine hématologique = Post-transfusional iron overload, iron loading anemiaROSE, C.La Revue de médecine interne (Paris). 2012, Vol 33, issn 0248-8663, S15-S18, SUP1Conference Paper

A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of Iron overload in patients with thalassemiaGALANELLO, Renzo; KATTAMIS, Antonis; PIGA, Antonio et al.Haematologica (Roma). 2006, Vol 91, Num 9, pp 1241-1243, issn 0390-6078, 3 p.Article

Deferiprone, efficacy and safetyCHOUDHRY, V. P; PATI, H. P; SAXENA, Anita et al.Indian journal of pediatrics. 2004, Vol 71, Num 3, pp 213-216, issn 0019-5456, 4 p.Article

Intensive chelation therapy in β-thalassemia and possible adverse cardiac effects of desferrioxamineAESSOPOS, Athanassios; KATI, Maria; FARMAKIS, Dimitrios et al.International journal of hematology. 2007, Vol 86, Num 3, pp 212-215, issn 0925-5710, 4 p.Article

Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in ratsAMMAR, El-Sayed M; SAID, Shehta A; SUDDEK, Ghada M et al.Canadian journal of physiology and pharmacology. 2011, Vol 89, Num 4, pp 269-276, issn 0008-4212, 8 p.Article

Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicityHASKOVA, Pavlina; KOUBKOVA, Lucie; VAVROVA, Anna et al.Toxicology (Amsterdam). 2011, Vol 289, Num 2-3, pp 122-131, issn 0300-483X, 10 p.Article

Iron-Related MRI Images in Patients with Pantothenate Kinase―Associated Neurodegeneration (PKAN) Treated with Deferiprone: Results of a Phase II Pilot TrialZORZI, Giovanna; ZIBORDI, Federica; SOLARI, Alessandra et al.Movement disorders. 2011, Vol 26, Num 9, pp 1756-1759, issn 0885-3185, 4 p.Article